Dr. Reddy's Laboratories Limited

NYSE:RDY

Drug Manufacturers - Specialty & Generic

Healthcare
$14.98 -1.13%

-$0.15 today

Market cap
$12.48B
Beta
0.26
P/E (TTM)
24.7
EPS (TTM)
$51.40
Dividend yield
0.63%
52W Low $12.19High $15.71

Volume 1.79M

Average 2.39M

RDY EBITDA Margin

EBITDA as a percentage of revenue.

Dr. Reddy's Laboratories LimitedNYSE: RDY

EBITDA Margin · Q2 FY2027 · quarter ended Sep 2026

EBITDA Margin narrows to 19.8%

EBITDA Margin was 19.8% in Q2 FY2027, down 7.8 pp from a year earlier. On a trailing-twelve-month basis it was 16.3%, down 12.5 pp year over year. Over 3 fiscal years it narrowed by 6.7 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2026 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 18 analysts of 21.1% for the fiscal year ending Mar 2027, down from 23.6% in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
19.8%+9.5 pp QoQ
Last fiscal yearMar 2026
23.6%-6.1 pp YoY
LTMSep 2026
16.3%-12.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-7.8 pp-0.9 pp+6.9 pp
1 year-6.1 pp-2.5 pp+3.7 pp
3 years-6.7 pp+2.1 pp+8.8 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2026
23.6%
Year-over-year change
-6.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How RDY compares with its peers on the latest reported figures

  • RDY's LTM Sep 2026 EBITDA Margin of 16.3% is the 7th highest of the 8 companies compared; the peer median is 20.9%.
  • Its year-over-year change of -12.5 pp is the 6th highest of 7, against a peer median of -1.2 pp.
  • Over three fiscal years its change of -6.7 pp compares with a peer median of +0.2 pp.
RDY Competitors Peer median
EBITDA Margin for RDY and competitors
Company Period LTM level YoY 3-year change
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202626.6% -9.0 pp+0.2 pp
ANIPANI Pharmaceuticals, Inc.LTM Mar 202625.4% +15.5 pp+15.5 pp
HLNHaleon plcLTM Jun 202524.4% —+6.0 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 202620.9% +0.5 pp+0.1 pp
BHCBausch Health Companies Inc.LTM Jun 202618.9% -14.3 pp-4.5 pp
VTRSViatris Inc.LTM Jun 202618.4% +21.9 pp-42.3 pp
RDYDr. Reddy's Laboratories LimitedLTM Sep 202616.3% -12.5 pp-6.7 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 202615.0% -2.9 pp+24.4 pp
Peer median (excluding RDY) 20.9%-1.2 pp+0.2 pp

Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

INR
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue214.39B245.88B279.16B325.54B353.47B
Cost of Revenue100.55B106.54B115.56B135.11B166.95B
Gross Profit113.84B139.34B163.61B190.43B186.52B
Gross Margin53.1%56.7%58.6%58.5%52.8%
Research & Development17.48B19.38B22.87B27.38B25.31B
Selling, General & Admin62.08B68.03B77.2B93.87B112.34B
Operating Expenses84.36B82.2B95.88B118.59B137.65B
Depreciation & Amortization11.82B12.64B14.84B17.06B21.68B
EBITDA45.08B74.43B88.42B96.67B83.29B
EBITDA Margin21.0%30.3%31.7%29.7%23.6%
Operating Income29.48B57.14B67.73B71.84B48.87B
Operating Margin13.7%23.2%24.3%22.1%13.8%
Interest Income965M1.18B2.28B2.68B8.28B
Interest Expense958M1.43B1.71B2.83B3.93B
Other Income / Expenses2.82B3.22B4.14B4.94B8.81B
Income Before Tax32.3B60.37B71.87B76.78B57.68B
Pre-Tax Margin15.1%24.6%25.7%23.6%16.3%
Income Tax Expense8.73B15.3B16.19B19.54B13B
Net Income23.57B45.07B55.68B56.54B45.09B
Net Margin11.0%18.3%19.9%17.4%12.8%
EPS (Basic)28.4254.2966.8067.8553.92
EPS (Diluted)28.3454.1766.8067.7753.92
Weighted Avg Shares829.41M830.17M833.54M833.31M832.41M
Weighted Avg Shares (Diluted)831.69M831.91M833.54M834.3M833.26M

Dr. Reddy's Laboratories Limited

NYSE:RDY

Intrinsic Alpha fair value

Locked

Current Price

$14.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.